Cannabis Law and Access in Ecuador

How Ecuador's cannabis law fits together

Forty-three countries have some form of regulated cannabis access at the time of writing. Ecuador is one of the more interesting cases, not because it is the most permissive, but because its cannabis law has changed unusually fast and is, frankly, a bit messy to track. Badly outdated summaries still circulate online, and the only reliable fix is to read the primary instruments, starting with the Ley Orgánica de Uso Médico del Cannabis y sus Derivados, and check them against secondary sources.

Before anything else: this article describes Ecuador's domestic legal framework only. It has no bearing on Australian law. Australian readers are subject to the Therapeutic Goods Administration's scheduling regime and the Poisons Standard. Cannabis and its derivatives remain tightly regulated here under Commonwealth and state law, regardless of what other countries do. If you want to understand how Australia's own access pathways work, our pages on the Special Access Scheme, Authorised Prescriber pathway, and the Schedule 8 (Controlled Drug) classification are the right starting point.

A useful habit when reading any foreign cannabis law is to separate three layers: the constitution, the statutes and regulations, and the court decisions that interpret them. Ecuador has all three moving at different speeds, which is why a single-sentence summary such as "Ecuador legalised cannabis" is almost always wrong.

The legal timeline: from prohibition to regulated access

Ecuador's story begins in the constitution. The 2008 Constitution of Ecuador, written in Montecristi, a small city on the Pacific coast, declared drug addiction a public health issue rather than a criminal one. That was a philosophically significant move, though it took years for cannabis-specific legislation to follow.

Personal possession of small quantities was decriminalised under reforms to the Código Orgánico Integral Penal (COIP) in 2015, which established quantity thresholds below which individuals would not face criminal prosecution. The thresholds, a few grams for cannabis, were not a legalisation. They were a diversion of low-level users away from the criminal justice system. Cultivation, supply, and commercial activity remained prohibited.

The terminology matters here. Decriminalisation removes or reduces criminal penalties for certain conduct, usually personal possession, while the underlying substance stays controlled. Legalisation creates a lawful framework in which production, sale and use can happen under rules. Plenty of commentary blurs the two, and that blurring is one of the most common mistakes in summaries of Ecuadorian law.

The bigger shift came in 2022. Ecuador's Ley Orgánica de Uso Médico del Cannabis y sus Derivados (Organic Law on Medicinal Use of Cannabis and its Derivatives) came into force, establishing a formal regulatory regime for the cultivation, processing, and commercialisation of cannabis for medicinal and scientific purposes. A subsequent implementing regulation, the Reglamento General, fleshed out the licensing categories and oversight structure. The regulatory body responsible for enforcement is ARCSA (the Agencia Nacional de Regulación, Control y Vigilancia Sanitaria), the Ecuadorian equivalent of a combined TGA/food standards authority.

If the TGA comparison is new to you, our explainer on the Therapeutic Goods Administration (TGA) sets out what an Australian regulator of this kind actually does, which makes ARCSA's combined role easier to picture.

What the 2022 law actually permits

The 2022 law created a tiered licensing structure. Broadly, licences fall into categories covering cultivation (with separate tiers for small community growers and larger commercial operations), processing and manufacture, and commercialisation. The law permits:

• Cultivation of cannabis plants for medicinal and scientific purposes, subject to ARCSA licensing and oversight
• Extraction and processing of cannabis derivatives, including cannabidiol (CBD) and other non-psychoactive compounds
• Manufacture of finished medicinal cannabis products intended for domestic use or export
• Import and export of cannabis derivatives under controlled conditions
• Scientific research under approved protocols

Recreational use remains prohibited. THC-containing products are restricted to the medicinal and scientific channels; the law does not create a recreational market of the kind seen in Canada or Uruguay. Personal possession at the decriminalised threshold still applies, but it is a threshold of tolerance rather than legalisation.

Tiered licensing is a common design in medicinal cannabis regimes, and the reasoning is straightforward. A small community grower and a large commercial operator pose different oversight challenges, so regulators tend to attach different security, record-keeping and quality obligations to each. When you read a licensing law, the questions worth asking are who can apply, what activity each licence covers, and who inspects. Whether a category exists on paper says little about whether licences are being issued in practice.

THC limits and the CBD distinction

One of the more consequential distinctions in the 2022 framework is between "psychoactive" cannabis (plants containing THC above a defined threshold) and hemp-derived or low-THC material. This mirrors regulatory frameworks in the EU and elsewhere: lower-THC plant material and CBD isolates face a lighter licensing burden than high-THC cultivars or extracts.

The implementing regulations set a 1% THC dry-weight threshold for "industrial hemp" classification, higher than the 0.3% limit used in the EU or the 0.2–0.3% threshold common in many jurisdictions, including the threshold relevant to Australian industrial hemp under state-based schemes. Products containing primarily cannabidiol with minimal THC sit in a less restricted category, though they still require ARCSA oversight for commercial sale.

Comparing thresholds across countries is a trap for the unwary. A number only means something alongside its measurement basis (dry weight of the plant material, or concentration in a finished product) and the category it unlocks. A higher hemp threshold in one country does not mean a more relaxed regime overall, because the rules for what happens above that line, and for the finished products, can differ sharply.

For products that include a broader phytochemical profile, what we'd describe in glossary terms as full-spectrum extracts, the regulatory requirements are more demanding. The chemistry of those products, including the presence of minor cannabinoids and terpenes like beta-caryophyllene or myrcene, doesn't change the law, but it does affect how products are classified and what testing requirements apply.

Access for patients: the medicinal pathway

For individuals seeking medicinal cannabis in Ecuador, access flows through the conventional prescription channel. A physician must prescribe; the product must be an ARCSA-authorised medicine or derivative. There is no equivalent to Australia's Special Access Scheme Category B self-referral mechanism, and there is no unregistered product pathway analogous to the TGA's SAS-A emergency access.

That contrast is easier to follow with the Australian side in view. Our pages on understanding the Special Access Scheme in Australia and the legal basis for unapproved therapeutic goods explain why Australia has routes for products that are not on the register, and why Ecuador's model, which routes everything through authorised medicines, is structurally different.

In practice, Ecuador's medicinal market is still maturing. The 2022 law created the legal scaffolding, but the number of locally licensed products has grown slowly. Import of approved foreign medicinal cannabis products is possible under the law, but the regulatory pathway for each product requires formal ARCSA evaluation, not a fast process. Patients and prescribers face real-world access gaps that the legal text alone doesn't resolve. That gap between what the law says and what's actually on the pharmacy shelf is, in my view, the most underreported aspect of cannabis reform globally. Ecuador is far from alone in that.

Constitutional protection of personal use: the 2023 court ruling

In 2023, Ecuador's Constitutional Court issued a significant ruling expanding the interpretation of personal possession rights. The Court found that personal possession and consumption of cannabis for recreational purposes, in quantities for personal use, falls within constitutionally protected personal autonomy rights under Article 66 of the 2008 Constitution. The ruling did not legalise recreational supply, cultivation for recreational purposes, or commercial sale. But it substantially shifted the legal ground for individual users.

This is an important nuance. The ruling creates a constitutional protection for the act of personal use and possession; it does not create a regulated market. Ecuador's legislature has not, as of mid-2025, passed legislation establishing recreational retail or commercial cultivation for recreational ends. The practical effect is that personal possession at individual-use quantities is constitutionally shielded from prosecution, but the supply side remains illegal. That tension, between constitutionally protected consumption and a prohibited supply chain, is legally and practically awkward. Other jurisdictions have found themselves in similar positions; it tends to push supply underground rather than resolve it.

Court rulings of this kind work differently from statutes. A constitutional decision sets a boundary on what the state may prosecute, but it does not write the licensing rules, the product standards or the retail framework that a legislature would have to design. Until lawmakers act, the ruling and the 2022 medicinal law sit side by side, covering different ground.

What this means for Australian readers (and what it doesn't)

Australian law does not change because Ecuador, or any other country, moves its own regulatory settings. An Australian travelling to Ecuador is subject to Ecuadorian law whilst in Ecuador, and to Australian law, including import controls, upon return. The Australian Border Force and the TGA's import regulations apply to any substance being brought back into the country. Cannabis and cannabis derivatives remain controlled substances under Australian law regardless of their legal status overseas. The Schedule 8 classification for THC-containing products and the prescription-only status of approved CBD medicines under Schedule 4 are not affected by Ecuador's domestic framework.

Part of the reason is how Australia's system is built. Scheduling decisions are made through the Poisons Standard, and the states and territories then apply them through their own legislation. Our explainers on the Poisons Standard (SUSMP) and state versus federal drug regulation in Australia show why a change overseas has no automatic effect here. Readers wanting the local picture in one place can also start with Medicinal Cannabis Access in Australia: FAQ.

What Ecuador's evolution does illustrate, and this is worth understanding, is the range of regulatory architectures that exist. The ARCSA licensing model, the constitutional court pathway, the distinction between medicinal and recreational regulatory streams: these are design choices, not inevitable outcomes. For anyone studying how the endocannabinoid system and its interactions with compounds like CBD or THC are being regulated globally, Ecuador is a genuinely instructive case study. Just keep it in its proper lane.

Sources

• Cannabis and Cannabis-Related Substances; World Health Organisation
• Cannabis, United Nations Office on Drugs and Crime
• Medicinal Cannabis Guidance Documents, Therapeutic Goods Administration (AU)
• Cannabis Policy in Latin America; NCBI/PubMed Central

Marcus Hale, Regulatory researcher, TGA & access law